Physiological Assessments During Non Operative Treatment on the Chest Wall Deformities

NCT ID: NCT02528656

Last Updated: 2024-04-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-12

Study Completion Date

2024-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The physiological assessment in non-operative treatment on chest wall deformities, are still unclear today. These functional benefits outweigh the aesthetic benefits associated with anatomical improvement. The functional benefits, ventilation, hemodynamic and neurologic, have never been evaluated.

Assessment of Effects on parasympathetic activity of the autonomic nervous system, global health criterion measured by noninvasive methods.

Anatomic evaluation, between the initial and final assessment by objective measures 1) of the chest wall by MRI, and 2) of the heart by echocardiography.

Noninvasive physiological assessment at rest and during exercise in respiratory function exploration flows and volumes, cardiac function by flow measurement, and overall metabolic function test effort (VO2max). Subjective assessment of functional gain between the initial and final balance sheet, based on EVA scales, valued by patients, parents and doctors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pectus Excavatum Pectus Carinatum

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pectus Excavatum

Patients with pectus excavatum who do not require surgery, will be treated with the Vacuum bell device.

Group Type EXPERIMENTAL

Vacuum Bell

Intervention Type DEVICE

Patients will be submitted to a negative pressure treatment with the Vacuum Bell device.

Pectus Carinatum

Patients with pectus carinatum who do not require surgery, will be treated with the Dynamic Compression System.

Group Type EXPERIMENTAL

Dynamic Compression System

Intervention Type DEVICE

Patients will be submitted to a dynamic compression system.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vacuum Bell

Patients will be submitted to a negative pressure treatment with the Vacuum Bell device.

Intervention Type DEVICE

Dynamic Compression System

Patients will be submitted to a dynamic compression system.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with pectus excavatum or pectus carinatum who does not require surgery
* Patient with sufficient displacement of the chest wall during an initial test carried out during the first consultation :For pectus carinatum correction must be obtained with a pressure lower than 9 psi (pound per square inch). For pectus excavatum less than 250 mbar depression.
* Signed informed consent
* Subject (or parents) affiliated to the French National Health Insurance

Exclusion Criteria

* Skeletal disease, disturbing bone strength as osteogenesis imperfect and osteoporosis.
* Uncontrolled coagulopathies.
* Marfan syndrome, with mitral valve prolapse for pectus Excavatum.
* Atrial fibrillation
* Taking antiarrhythmic drug.
Minimum Eligible Age

10 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

MEDICALEX

UNKNOWN

Sponsor Role collaborator

Centre Hospitalier Universitaire de Saint Etienne

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Manuel LOPEZ, MD

Role: STUDY_CHAIR

CHU de SAINT-ETIENNE

Arnaud PATOIR, MD

Role: PRINCIPAL_INVESTIGATOR

CHU SAINT-ETIENNE

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU de SAINT-ETIENNE

Saint-Etienne, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Arnaud PATOIR, MD

Role: CONTACT

(0)477828847 ext. +33

Arnauld GARCIN, CRA

Role: CONTACT

(0)477120286 ext. +33

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2014-A00841-46

Identifier Type: OTHER

Identifier Source: secondary_id

1408081

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.